| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | -0.034 | 0.4 |
| mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | 0.028 | 0.4 |
| mRNA | ruxolitinib | CTRPv2 | pan-cancer | AAC | -0.031 | 0.4 |
| mRNA | BRD9876:MK-1775 (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.12 | 0.4 |
| mRNA | elocalcitol | CTRPv2 | pan-cancer | AAC | 0.031 | 0.4 |
| mRNA | ifosfamide | CTRPv2 | pan-cancer | AAC | -0.048 | 0.4 |
| mRNA | BHG712 | GDSC1000 | pan-cancer | AAC | -0.026 | 0.4 |
| mRNA | ML006 | CTRPv2 | pan-cancer | AAC | -0.033 | 0.4 |
| mRNA | PIK-93 | GDSC1000 | pan-cancer | AAC | 0.025 | 0.4 |
| mRNA | Pazopanib | GDSC1000 | pan-cancer | AAC | -0.03 | 0.4 |